These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30867522)

  • 61. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review.
    Ren X; Wei X; Ding Y; Qi F; Zhang Y; Hu X; Qin C; Li X
    Onco Targets Ther; 2019; 12():733-744. PubMed ID: 30774360
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
    Chandhok NS; Saif MW
    JOP; 2014 Mar; 15(2):91-4. PubMed ID: 24618425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neoadjuvant therapy vs. upfront surgery for resectable pancreatic cancer: An update on a systematic review and meta-analysis.
    Xu Y; Chen Y; Han F; Wu J; Zhang Y
    Biosci Trends; 2022 Jan; 15(6):365-373. PubMed ID: 34759120
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
    Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
    Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Resection for advanced pancreatic cancer following multimodal therapy].
    Kleeff J; Stöß C; Yip V; Knoefel WT
    Chirurg; 2016 May; 87(5):406-12. PubMed ID: 27138271
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of surgery in pancreatic cancer.
    Buanes TA
    World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
    Tang K; Lu W; Qin W; Wu Y
    Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 72. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis.
    Xu CP; Xue XJ; Liang N; Xu DG; Liu FJ; Yu XS; Zhang JD
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):549-59. PubMed ID: 24370686
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trends in Neoadjuvant Approaches in Pancreatic Cancer.
    Du L; Wang-Gillam A
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1070-1077. PubMed ID: 28784867
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer.
    Asare EA; Evans DB; Erickson BA; Aburajab M; Tolat P; Tsai S
    J Surg Oncol; 2016 Sep; 114(3):291-5. PubMed ID: 27264017
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Systematic review and meta-analysis of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials.
    Lim Khai Shin A; Ho Si Ying A; Neo Hui Wen S; Yeo SC; Tay KV
    J Gastrointest Surg; 2023 Jun; 27(6):1261-1276. PubMed ID: 36882627
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Resection and radiochemotherapy of pancreatic cancer--the future?
    Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG
    Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.
    Zhan HX; Xu JW; Wu D; Wu ZY; Wang L; Hu SY; Zhang GY
    Cancer Med; 2017 Jun; 6(6):1201-1219. PubMed ID: 28544758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.